Compare CSX Corporation (CSX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Sana Biotechnology Inc — how do they compare? CSX Corporation trades at $50.1 (market cap $92.55B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: CSX Corporation is far larger — about 81.9× Sana Biotechnology Inc's market cap, and CSX Corporation pays a 1.12% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CSX | SANA | |
|---|---|---|
Market Cap | $92.55B | $1.13B |
Sector | Industrials | Health |
52-Week High | $53.21 | $5.92 |
52-Week Low | $32.05 | $2.68 |
Enterprise Value | $110.52B | $1.05B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.09, down slightly by 0.06% today, with a neutral technical signal. Recent Q2 2026 earnings beat expectations with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and improved margins. Analyst consensus is bullish with a $52.57 price target, supported by strong cash flow trends and a 58.69% buy rating from coverage.
The outlook is positive due to volume growth and cost controls, but risks include fuel cost pressures and competitive freight markets. With a P/E of 29.05 above industry averages, the stock offers growth potential if earnings momentum continues, though high debt levels warrant monitoring.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
